See more : Shanghai Jiaoda Onlly Co.,Ltd (600530.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Pharmicell Co., Ltd. (005690.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pharmicell Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Japan Tobacco Inc. (2914.T) Income Statement Analysis – Financial Results
- Rain Industries Limited (RAIN.BO) Income Statement Analysis – Financial Results
- Seco S.p.A. (IOT.MI) Income Statement Analysis – Financial Results
- Citrix Systems, Inc. (CTXS) Income Statement Analysis – Financial Results
- NB Private Equity Partners Limited (NBPU.L) Income Statement Analysis – Financial Results
Pharmicell Co., Ltd. (005690.KS)
About Pharmicell Co., Ltd.
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 56.23B | 60.18B | 50.89B | 37.75B | 32.48B | 28.35B | 25.20B | 27.84B | 25.18B | 20.16B | 33.41B | 11.11B | 10.28B | 6.37B | 7.19B | 8.33B | 12.26B |
| Cost of Revenue | 41.27B | 36.36B | 27.44B | 19.97B | 19.45B | 16.55B | 17.13B | 17.62B | 19.62B | 16.31B | 24.66B | 9.78B | 11.91B | 4.64B | 5.06B | 6.24B | 7.03B |
| Gross Profit | 14.96B | 23.82B | 23.46B | 17.78B | 13.03B | 11.80B | 8.07B | 10.22B | 5.55B | 3.85B | 8.75B | 1.33B | -1.63B | 1.73B | 2.13B | 2.08B | 5.23B |
| Gross Profit Ratio | 26.60% | 39.58% | 46.09% | 47.09% | 40.12% | 41.63% | 32.02% | 36.70% | 22.05% | 19.09% | 26.19% | 11.95% | -15.82% | 27.12% | 29.58% | 25.01% | 42.69% |
| Research & Development | 6.86B | 6.88B | 6.99B | 4.31B | 4.87B | 4.51B | 3.60B | 2.73B | 1.76B | 1.22B | 762.26M | 418.36M | 366.60M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.62B | 1.50B | 384.60M | 347.76M | 448.88M | 551.11M | 483.14M | 605.89M | 726.78M | 670.57M | 1.21B | 1.08B | 1.03B | 597.63M | 266.69M | 241.78M | 336.05M |
| Selling & Marketing | 1.35B | 908.53M | 1.68B | 1.16B | 1.21B | 2.13B | 1.59B | 1.87B | 1.48B | 2.68B | 2.82B | 3.38B | 3.64B | 2.96B | 2.00B | 3.03B | 4.38B |
| SG&A | 7.14B | 2.41B | 2.06B | 1.51B | 1.66B | 2.68B | 2.07B | 2.48B | 2.21B | 3.35B | 4.03B | 4.46B | 4.67B | 3.56B | 2.27B | 3.27B | 4.72B |
| Other Expenses | 0.00 | 5.65B | 6.79B | 4.73B | 4.53B | -36.30M | 17.35M | 838.85M | -818.23M | -3.09B | 182.24M | -257.08M | 108.97M | -1.13B | 400.60M | 540.68M | 1.66B |
| Operating Expenses | 14.00B | 14.95B | 15.84B | 10.55B | 11.07B | 11.54B | 12.53B | 12.08B | 11.08B | 12.27B | 16.39B | 15.36B | 13.57B | 10.92B | 4.61B | 5.42B | 7.30B |
| Cost & Expenses | 55.28B | 51.31B | 43.28B | 30.52B | 30.52B | 28.09B | 29.66B | 29.70B | 30.71B | 28.57B | 41.04B | 25.14B | 25.48B | 15.56B | 9.68B | 11.67B | 14.33B |
| Interest Income | 273.80M | 330.83M | 197.37M | 166.36M | 217.02M | 164.84M | 180.12M | 197.35M | 261.59M | 252.17M | 470.98M | 600.20M | 337.09M | 263.45M | 71.85M | 295.52M | 104.51M |
| Interest Expense | 866.88M | 746.20M | 1.68B | 84.89M | 101.30M | 56.76M | 3.00 | 185.68M | 445.73M | 912.34M | 1.96B | 1.92B | 1.78B | 1.00B | 660.10M | 582.35M | 331.68M |
| Depreciation & Amortization | 2.84B | 2.19B | 1.74B | 1.77B | 1.70B | 1.62B | 3.33B | 3.35B | 2.59B | 2.79B | 3.60B | 2.85B | 1.25B | 436.10M | 267.80M | 535.28M | 734.71M |
| EBITDA | 8.44B | 8.90B | 12.87B | 7.10B | 4.25B | -11.00B | -1.23B | 2.86B | -3.35B | -25.07B | -20.14B | -11.91B | -15.44B | -12.40B | -3.01B | -1.88B | 159.00M |
| EBITDA Ratio | 15.01% | 22.74% | 22.85% | 20.59% | 13.51% | 7.51% | 132.01% | 10.23% | -13.32% | -45.33% | -13.03% | -106.93% | -138.50% | -192.97% | -35.47% | -23.50% | 3.62% |
| Operating Income | 951.00M | 8.87B | 7.61B | 7.23B | 1.96B | 260.18M | -4.46B | -1.87B | -5.53B | -8.42B | -7.64B | -14.03B | -16.31B | -9.19B | -2.49B | -3.34B | -2.06B |
| Operating Income Ratio | 1.69% | 14.74% | 14.95% | 19.16% | 6.05% | 0.92% | -17.70% | -6.70% | -21.97% | -41.76% | -22.86% | -126.28% | -158.62% | -144.31% | -34.59% | -40.11% | -16.83% |
| Total Other Income/Expenses | 3.78B | -2.90B | 1.65B | -1.99B | 479.54M | -12.94B | -17.40B | 1.19B | -858.20M | -20.35B | -18.06B | -2.65B | -2.16B | -4.64B | -1.45B | 338.91M | 1.16B |
| Income Before Tax | 4.73B | 5.97B | 9.51B | 5.24B | 2.44B | -12.68B | -39.20B | -676.71M | -6.39B | -28.77B | -25.70B | -16.68B | -18.47B | -13.83B | -3.93B | -3.00B | -907.86M |
| Income Before Tax Ratio | 8.42% | 9.92% | 18.69% | 13.88% | 7.52% | -44.73% | -155.56% | -2.43% | -25.38% | -142.73% | -76.94% | -150.11% | -179.64% | -217.19% | -54.72% | -36.04% | -7.40% |
| Income Tax Expense | 1.15B | -4.92B | 377.72M | 761.95M | -1.90B | -12.88B | 34.40B | 1.37B | -412.47M | -3.51B | -313.52M | 969.80M | -285.47M | -3.54B | 19.52M | 2.28B | 1.77B |
| Net Income | 3.58B | 8.26B | 9.45B | 5.24B | 4.35B | -12.68B | -39.20B | -676.71M | -6.39B | -28.77B | -25.70B | -17.64B | -18.17B | -13.83B | -3.95B | -4.43B | -907.86M |
| Net Income Ratio | 6.36% | 13.73% | 18.57% | 13.88% | 13.38% | -44.73% | -155.56% | -2.43% | -25.38% | -142.73% | -76.94% | -158.77% | -176.74% | -217.19% | -54.99% | -53.23% | -7.40% |
| EPS | 60.00 | 137.79 | 157.66 | 87.44 | 72.52 | -214.00 | -671.27 | -12.00 | -115.17 | -619.00 | -607.88 | -467.00 | -694.74 | -667.50 | -257.50 | -265.30 | -68.80 |
| EPS Diluted | 59.63 | 137.79 | 157.66 | 87.44 | 72.52 | -214.00 | -671.10 | -12.00 | -115.00 | -619.00 | -607.88 | -467.00 | -694.74 | -667.50 | -257.50 | -265.30 | -68.80 |
| Weighted Avg Shares Out | 59.63M | 59.96M | 59.95M | 59.95M | 59.95M | 59.26M | 58.39M | 56.39M | 55.49M | 46.48M | 42.28M | 37.78M | 26.16M | 20.72M | 15.35M | 16.71M | 13.20M |
| Weighted Avg Shares Out (Dil) | 60.00M | 59.96M | 59.95M | 59.95M | 59.95M | 59.26M | 58.41M | 56.39M | 55.57M | 46.48M | 42.28M | 37.78M | 26.16M | 20.72M | 15.35M | 16.71M | 13.20M |
Source: https://incomestatements.info
Category: Stock Reports